Germline HOXB13 mutation p.G84E do not confer an increased bladder or kidney cancer risk in polish population
Menée en Pologne sur la période 2000-2018 auprès de 813 patients atteints d'un cancer du rein, 1 418 patients atteints d'un cancer de la vessie et de 4 497 témoins (âge moyen au diagnostic : 63 ou 69 ans selon la localisation), cette étude analyse la prévalence de la mutation G84E du gène HOXB13
Introduction: The role of HOXB13 in bladder and renal tumorigenesis is unclear. Our goal was to determine the prevalence of HOXB13 p.G84E mutation in bladder and kidney cancer patients from Poland. Materials and methods: 1418 patients with bladder cancer and 813 cases with kidney cancer and 4497 controls were genotyped for HOXB13 p.G84E. Results: p.G84E mutation of HOXB13 gene was detected in three of 1418 (0.2%) bladder cancer cases and in six of 4497 controls (odds ratio [OR], 1.6; 95% CI 0.39–6.36; p = 0.8). Among 813 kidney cancer cases HOXB13 mutations was reported in three patients (0,4%) (odds ratio [OR], (OR = 2,8; 95% CI 0.69–11.11; p = 0.3). In cases with mutations in the HOXB13 gene, the family history of cancer was negative. Conclusion: HOXB13 mutation was not associated with bladder or kidney cancer. Mutation p.G84E in HOXB13 seem not to play a role in bladder and kidney cancer development in Polish patients.